CA2980266C - Condensed tricyclic derivatives of 1-(cyclo)alkyl-pyridine-2-one are useful in cancer treatment. - Google Patents
Condensed tricyclic derivatives of 1-(cyclo)alkyl-pyridine-2-one are useful in cancer treatment.Info
- Publication number
- CA2980266C CA2980266C CA2980266A CA2980266A CA2980266C CA 2980266 C CA2980266 C CA 2980266C CA 2980266 A CA2980266 A CA 2980266A CA 2980266 A CA2980266 A CA 2980266A CA 2980266 C CA2980266 C CA 2980266C
- Authority
- CA
- Canada
- Prior art keywords
- oxo
- methyl
- methoxy
- alkyl
- azepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1636CH2015 | 2015-03-30 | ||
| IN1636/CHE/2015 | 2015-03-30 | ||
| PCT/IN2016/050098 WO2016157221A1 (en) | 2015-03-30 | 2016-03-30 | Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2980266A1 CA2980266A1 (en) | 2016-10-06 |
| CA2980266C true CA2980266C (en) | 2025-05-06 |
Family
ID=56015058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2980266A Active CA2980266C (en) | 2015-03-30 | 2016-03-30 | Condensed tricyclic derivatives of 1-(cyclo)alkyl-pyridine-2-one are useful in cancer treatment. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10689390B2 (enExample) |
| EP (1) | EP3277683B1 (enExample) |
| JP (1) | JP6764877B2 (enExample) |
| KR (1) | KR102588109B1 (enExample) |
| CN (1) | CN107548393B (enExample) |
| AU (1) | AU2016242473B2 (enExample) |
| BR (1) | BR112017020739B1 (enExample) |
| CA (1) | CA2980266C (enExample) |
| DK (1) | DK3277683T3 (enExample) |
| ES (1) | ES2911886T3 (enExample) |
| IL (1) | IL254528B (enExample) |
| MX (1) | MX376112B (enExample) |
| PL (1) | PL3277683T3 (enExample) |
| PT (1) | PT3277683T (enExample) |
| RU (1) | RU2721120C2 (enExample) |
| WO (1) | WO2016157221A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61803B1 (sr) * | 2015-09-09 | 2021-06-30 | Jubilant Biosys Ltd | Triciklični fuzioni piridin-2-on derivati i njihova upotreba kao inhibitora brd4 |
| RU2019117356A (ru) * | 2016-11-10 | 2020-12-10 | Лосинь Фармасьютикал (Шанхай) Ко., Лтд. | Азотсодержащее макроциклическое соединение, способ его получения, фармацевтическая композиция и применение |
| CN111819181A (zh) * | 2018-05-10 | 2020-10-23 | 罗欣药业(上海)有限公司 | 苯并七元杂环类化合物、其制备方法、药物组合物及应用 |
| CN110172068A (zh) * | 2019-06-05 | 2019-08-27 | 河南龙湖生物技术有限公司 | 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用 |
| US12527741B2 (en) | 2021-06-17 | 2026-01-20 | Wisconsin Alumni Research Foundation | Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1545767A (en) * | 1976-06-30 | 1979-05-16 | Aspro Nicholas Ltd | Isoquinoline derivatives |
| WO2008133288A1 (ja) | 2007-04-25 | 2008-11-06 | Daiichi Sankyo Company, Limited | 三環性アリール化合物 |
| ES2480994T3 (es) | 2008-03-31 | 2014-07-29 | Genentech, Inc. | Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso |
| EP2585465B1 (en) | 2010-06-22 | 2014-11-12 | GlaxoSmithKline LLC | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| CA2901352A1 (en) * | 2013-02-19 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines |
| BR112015022391B1 (pt) * | 2013-03-12 | 2021-12-21 | Abbvie Inc | Compostos inibidores do domínio bromo tetracíclico, composição farmacêutica que compreende os referidos compostos e usos terapêuticos dos mesmos |
| WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
| US9814728B2 (en) * | 2013-09-20 | 2017-11-14 | Saint Louis University | Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi) |
-
2016
- 2016-03-30 KR KR1020177031273A patent/KR102588109B1/ko active Active
- 2016-03-30 CN CN201680020269.3A patent/CN107548393B/zh active Active
- 2016-03-30 US US15/562,381 patent/US10689390B2/en active Active
- 2016-03-30 ES ES16723536T patent/ES2911886T3/es active Active
- 2016-03-30 JP JP2017551712A patent/JP6764877B2/ja active Active
- 2016-03-30 DK DK16723536.5T patent/DK3277683T3/da active
- 2016-03-30 WO PCT/IN2016/050098 patent/WO2016157221A1/en not_active Ceased
- 2016-03-30 PT PT167235365T patent/PT3277683T/pt unknown
- 2016-03-30 MX MX2017012387A patent/MX376112B/es active IP Right Grant
- 2016-03-30 CA CA2980266A patent/CA2980266C/en active Active
- 2016-03-30 AU AU2016242473A patent/AU2016242473B2/en active Active
- 2016-03-30 EP EP16723536.5A patent/EP3277683B1/en active Active
- 2016-03-30 RU RU2017135205A patent/RU2721120C2/ru active
- 2016-03-30 PL PL16723536T patent/PL3277683T3/pl unknown
- 2016-03-30 BR BR112017020739-7A patent/BR112017020739B1/pt active IP Right Grant
-
2017
- 2017-09-17 IL IL254528A patent/IL254528B/en active IP Right Grant
-
2020
- 2020-05-07 US US16/869,517 patent/US11319326B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017135205A3 (enExample) | 2019-07-17 |
| KR20170132278A (ko) | 2017-12-01 |
| IL254528A0 (en) | 2017-11-30 |
| IL254528B (en) | 2020-11-30 |
| US20180282345A1 (en) | 2018-10-04 |
| RU2017135205A (ru) | 2019-04-10 |
| AU2016242473A1 (en) | 2017-10-26 |
| US20200331926A1 (en) | 2020-10-22 |
| MX2017012387A (es) | 2018-06-11 |
| AU2016242473B2 (en) | 2020-06-25 |
| KR102588109B1 (ko) | 2023-10-12 |
| MX376112B (es) | 2025-03-07 |
| JP2018510203A (ja) | 2018-04-12 |
| US11319326B2 (en) | 2022-05-03 |
| HK1248686A1 (zh) | 2018-10-19 |
| DK3277683T3 (en) | 2022-05-02 |
| CN107548393A (zh) | 2018-01-05 |
| EP3277683B1 (en) | 2022-03-09 |
| ES2911886T3 (es) | 2022-05-23 |
| EP3277683A1 (en) | 2018-02-07 |
| CN107548393B (zh) | 2021-03-02 |
| US10689390B2 (en) | 2020-06-23 |
| NZ735972A (en) | 2024-08-30 |
| JP6764877B2 (ja) | 2020-10-07 |
| BR112017020739A2 (pt) | 2018-07-17 |
| PT3277683T (pt) | 2022-06-28 |
| PL3277683T3 (pl) | 2022-05-23 |
| CA2980266A1 (en) | 2016-10-06 |
| BR112017020739B1 (pt) | 2023-03-14 |
| WO2016157221A1 (en) | 2016-10-06 |
| RU2721120C2 (ru) | 2020-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11319326B2 (en) | Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer | |
| US11267820B2 (en) | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | |
| ES2823477T3 (es) | Aril éteres y usos de los mismos | |
| WO2016131381A1 (en) | Fused-ring compounds, pharmaceutical composition and uses thereof | |
| JP7624404B2 (ja) | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 | |
| WO2012117421A1 (en) | Histone deacetylase inhibitors | |
| CA3045855A1 (en) | Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof | |
| WO2016140501A1 (en) | Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors | |
| CA3223874A1 (en) | Pyrimidine compounds for use as map4k1 inhibitors | |
| HK1248686B (en) | Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer | |
| BR112018004338B1 (pt) | Derivados de piridin-2-ona tricíclica fundida, composição, método e seu uso como inibidores de brd4 | |
| HK1251562B (en) | Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250226 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250226 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20250314 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250502 |
|
| Q17 | Modified document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED Effective date: 20250505 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE Effective date: 20250506 |